Alectinib vs Ceritinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline
Alectinib · Alecensa
Marketed by Roche and partners
NCT02075840 · Phase 3 · completed
Participants were randomly assigned to alectinib or the active comparator crizotinib (152 versus 151), but the trial was open-label rather than double-blind. The primary progression-free survival endpoint was met, with alectinib showing a hazard ratio of 0.47 versus crizotinib (p<0.0001), but the lack of blinding limits the overall evidence strength.
Next expected readout: November 2026 · NCT04302025 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 (From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months)): Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019). (met)
Result source: NCT02838420
Ceritinib
Marketed by Novartis
NCT01828099 · Phase 3 · completed
The trial was randomized and actively controlled, with 189 patients assigned to ceritinib and 187 to chemotherapy, but treatment was open-label rather than double-blind. Its clinical primary endpoint, progression-free survival assessed by an independent review committee, was met: median progression-free survival was 16.6 versus 8.1 months, with hazard ratio 0.55 (95% CI 0.42–0.73; p<0.001).
Next expected readout: December 2026 · NCT02321501 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1) (met)
Result source: NCT01828099
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alectinib | Ceritinib |
|---|---|---|
| PFS, median | 10.9 vs 1.4vs Premetrexed/DocetaxelNCT026043425 other results
| 16.6 vs 8.1vs ChemotherapyNCT0182809910 other results
|
| OS, median | 81.1 vs 54.2vs CrizotinibNCT020758403 other results
| 62.9 vs 40.7vs ChemotherapyNCT018280995 other results
|
| ORR | 82.9% vs 75.5%vs CrizotinibNCT020758409 other results
| 72.5% vs 26.7%vs ChemotherapyNCT0182809912 other results
|
| Duration of response, median | 42.3 vs 11.1vs CrizotinibNCT020758403 other results
| 23.9 vs 11.1vs ChemotherapyNCT0182809912 other results
|
PFS, median
- Alectinib
- 10.9 vs 1.4vs Premetrexed/DocetaxelNCT02604342
5 other results
- 25.7 vs 10.4 NCT02075840
- 7.1 vs 1.6 NCT02604342
- 8.2 NCT01871805
- 8.4 NCT01871805
- 8.9 NCT01801111
- Ceritinib
- 16.6 vs 8.1vs ChemotherapyNCT01828099
10 other results
- 5.4 vs 1.6 NCT01828112
- 16.8 vs 7.2 NCT01828099
- 6.2 vs 1.6 NCT01828112
- 5.8 NCT01685060
- 7.4 NCT01685060
- 15.2 NCT01283516
- 19.3 NCT01283516
- 7.2 NCT02040870
- 3.8 NCT02040870
- 3.7 NCT02450903
OS, median
- Alectinib
- 81.1 vs 54.2vs CrizotinibNCT02075840
3 other results
- 27.8 NCT02604342
- 27.9 NCT01871805
- 29.2 NCT01801111
- Ceritinib
- 62.9 vs 40.7vs ChemotherapyNCT01828099
5 other results
- 17.7 vs 20.1 NCT01828112
- 15.6 NCT01685060
- 51.3 NCT01685138
- 17.5 NCT02040870
- 17.3 NCT02450903
ORR
- Alectinib
- 82.9% vs 75.5%vs CrizotinibNCT02075840
9 other results
- 48.1% vs 0% NCT02604342
- 52.2% NCT01871805
- 50.8% NCT01801111
- 44.8% NCT01801111
- 52.9% NCT01871805
- 51.4% NCT01801111
- 50% NCT01801111
- 73.1% NCT01801111
- 57.1% NCT01801111
- Ceritinib
- 72.5% vs 26.7%vs ChemotherapyNCT01828099
12 other results
- 73.5% vs 33.2% NCT01828099
- 40.9% vs 6.9% NCT01828112
- 44.3% vs 6.9% NCT01828112
- 40.7% NCT01685060
- 67.7% NCT01685138
- 25% NCT02450903
- 35.7% NCT01685060
- 73.5% NCT01283516
- 65.1% NCT01283516
- 63.7% NCT01685138
- 41.7% NCT02040870
- 32% NCT02040870
Duration of response, median
- Alectinib
- 42.3 vs 11.1vs CrizotinibNCT02075840
3 other results
- 14.9 NCT01871805
- 13.3 NCT01871805
- 15.2 NCT01801111
- Ceritinib
- 23.9 vs 11.1vs ChemotherapyNCT01828099
12 other results
- 22.6 vs 9.8 NCT01828099
- 7.6 vs 10.4 NCT01828112
- 6.7 vs 8.3 NCT01828112
- 10.6 NCT01685060
- 12.9 NCT01685060
- 14.2 NCT01283516
- 21.8 NCT01283516
- 24 NCT01685138
- 27.3 NCT01685138
- 7.5 NCT02040870
- 9.2 NCT02040870
- 6.3 NCT02450903
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety
Coverage. Alectinib: 10 of 10 rows · Ceritinib: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alectinib Rows use multiple source trials | Ceritinib Rows use multiple source trials |
|---|---|---|
| Disease Control responder rate · % of participants | 82.7% (n=52) vs 25% (n=28) Premetrexed/Docetaxela,b,c NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 | 84.7% (n=189) vs 73.8% (n=187) Chemotherapyd,a,b,c NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more dose89.4% (n=189) vs 75.9% (n=187) Chemotherapy NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Disease Control responder rate · % of participants No placebo or comparator arm | 66.7% (n=87)600 mg (Fed)e,f,b,c NCT01871805 · Phase 1/2 · registry result, not featured evidence | 70% (n=20)e,f,b,c NCT02450903 · Phase 2 · registry result, not featured evidence 2 other source trials77.7% (n=103) NCT02040870 · Phase 1/2 · registry result, not featured evidence 67% (n=103) NCT02040870 · Phase 1/2 · registry result, not featured evidence |
| Duration of Response time to event · months No placebo or comparator arm | 15.2 monthsg,h,b,c NCT01801111 · Phase 1/2 2 other source trials14.9 months600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence 13.3 months600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | 14.19 monthsd,g,h,b,c NCT01283516 · Phase 1 show 1 more dose21.75 months NCT01283516 · Phase 1 |
| ORR responder rate · % of participants No placebo or comparator arm | 50.8% (n=122)d,g,h,b,c NCT01801111 · Phase 1/2 show 5 more doses44.8% (n=96) NCT01801111 · Phase 1/2 73.1% (n=26) NCT01801111 · Phase 1/2 51.4% (n=138) NCT01801111 · Phase 1/2 50% (n=110) NCT01801111 · Phase 1/2 57.1% (n=28) NCT01801111 · Phase 1/2 | 73.5% (n=83)d,g,h,b,c NCT01283516 · Phase 1 show 1 more dose65.1% (n=83) NCT01283516 · Phase 1 |
| Overall Survival time to event · months No placebo or comparator arm | 29.2 monthse,f,b,c NCT01801111 · Phase 1/2 1 other source trial27.9 months600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | 17.3 monthse,f,b,c NCT02450903 · Phase 2 · registry result, not featured evidence 3 other source trials51.3 months NCT01685138 · Phase 2 · registry result, not featured evidence 15.6 months @ 24wk750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 17.5 months NCT02040870 · Phase 1/2 · registry result, not featured evidence |
| PFS time to event · months No placebo or comparator arm | 8.9 monthsg,h,b,c NCT01801111 · Phase 1/2 2 other source trials8.2 months600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence 8.4 months600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | 15.21 monthsd,g,h,b,c NCT01283516 · Phase 1 show 1 more dose19.32 months NCT01283516 · Phase 1 |
| Dropout rate | n/a: no completion milestonei NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 4 more resultsn/a: no completion milestone NCT02838420 · Phase 3 · monotherapy 54.4% NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone NCT01801111 · Phase 1/2 —600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | n/a: no completion milestonej NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 17 more resultsn/a: no completion milestoneCeritinib NCT01828112 · Phase 3 · monotherapy —Ceritinib (On-treatment) NCT01828112 · Phase 3 n/a: no completion milestone750 mg NCT01283516 · Phase 1 n/a: no completion milestone700 mg NCT01283516 · Phase 1 n/a: no completion milestone600 mg NCT01283516 · Phase 1 n/a: no completion milestone500 mg NCT01283516 · Phase 1 n/a: no completion milestone400 mg NCT01283516 · Phase 1 n/a: no completion milestone300 mg NCT01283516 · Phase 1 n/a: no completion milestone200 mg NCT01283516 · Phase 1 n/a: no completion milestone100 mg NCT01283516 · Phase 1 n/a: no completion milestone50 mg NCT01283516 · Phase 1 n/a: no completion milestone NCT02450903 · Phase 2 · registry result, not featured evidence 74.2%LDK378 (Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence —LDK378 Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence —750 mg NCT01685060 · Phase 2 · registry result, not featured evidence n/a: no completion milestone750 mg NCT01685060 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT02040870 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%i NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 4 more results— NCT02838420 · Phase 3 · monotherapy — NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 8.7% NCT01801111 · Phase 1/2 —600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | 12.7%j NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 17 more results6.1%Ceritinib NCT01828112 · Phase 3 · monotherapy —Ceritinib (On-treatment) NCT01828112 · Phase 3 11%750 mg NCT01283516 · Phase 1 0%700 mg NCT01283516 · Phase 1 20%600 mg NCT01283516 · Phase 1 0%500 mg NCT01283516 · Phase 1 0%400 mg NCT01283516 · Phase 1 0%300 mg NCT01283516 · Phase 1 0%200 mg NCT01283516 · Phase 1 0%100 mg NCT01283516 · Phase 1 0%50 mg NCT01283516 · Phase 1 15% NCT02450903 · Phase 2 · registry result, not featured evidence 14.5%LDK378 (Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence —LDK378 Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence —750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 8.6%750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 6.8% NCT02040870 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 46.1%i NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 4 more results15.2% NCT02838420 · Phase 3 · monotherapy 26% NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 28.3% NCT01801111 · Phase 1/2 24.1%600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | 49.2%j NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 17 more results—Ceritinib NCT01828112 · Phase 3 · monotherapy 49.6%Ceritinib (On-treatment) NCT01828112 · Phase 3 56.9%750 mg NCT01283516 · Phase 1 60%700 mg NCT01283516 · Phase 1 70%600 mg NCT01283516 · Phase 1 40%500 mg NCT01283516 · Phase 1 50%400 mg NCT01283516 · Phase 1 33.3%300 mg NCT01283516 · Phase 1 33.3%200 mg NCT01283516 · Phase 1 50%100 mg NCT01283516 · Phase 1 0%50 mg NCT01283516 · Phase 1 45% NCT02450903 · Phase 2 · registry result, not featured evidence —LDK378 (Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence 40.3%LDK378 Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence 47.9%750 mg NCT01685060 · Phase 2 · registry result, not featured evidence —750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 35% NCT02040870 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | i constipation 40.1% anaemia 27.6% blood bilirubin increased 24.3% NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 4 more resultsaspartate aminotransferase increased 52% blood bilirubin increased 48.8% blood creatine phosphokinase increased 44% NCT02838420 · Phase 3 · monotherapy constipation 20.8% anaemia 15.6% myalgia 14.3% NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 600 mg (Fed) fatigue 41.4% constipation 39.1% headache 28.7% NCT01871805 · Phase 1/2 · registry result, not featured evidence | j diarrhoea 84.7% nausea 68.8% vomiting 67.2% NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 14 more resultsdiarrhoea 85.5% nausea 78.2% vomiting 71.8% NCT01685138 · Phase 2 · registry result, not featured evidence 750 mg diarrhoea 82.1% nausea 82.1% vomiting 65.7% NCT01685060 · Phase 2 · registry result, not featured evidence diarrhoea 74.8% vomiting 61.2% alanine aminotransferase increased 59.2% NCT02040870 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation context differs: prior_therapy differs (naive versus experienced).
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 2 versus Phase 1/2.
- fPopulation comparability has not been reviewed for both studies.
- gTrial phases differ: Phase 1 versus Phase 1/2.
- hPopulation context differs: registered conditions differ.
- iPopulation comparability has not been reviewed for 3 of these studies.
- jPopulation comparability has not been reviewed for 17 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alectinib
show 1 more result
+ 625 further endpoints in the CSV export.
Ceritinib
show 3 more results
show 6 more results
show 6 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alectinib's landscape · Ceritinib's landscape